Investors Still Waiting on a ‘Land Grab’ for Biotechs
Mergers and acquisitions have always been a regular staple in the biotech industry. However, the speculation that a “land grab” for attractive and product rich biotechnology companies would gather steam in the third quarter has not panned out so far. In fact, the list of companies that investors are betting on that will be take-out targets remains longer than the actual number of consummated deals.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter